ArticleClinical ophthalmology (Auckland, N.Z.)2026
Retrospective Analysis of 5-Year Outcomes with the Hydrus Microstent in Combination with Cataract Surgery.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the efficacy of the Hydrus microstent in conjunction with cataract surgery over a period of 5 years. Methods: This was a retrospective, single site study. Eligible charts were from adults that had a diagnosis of mild to severe primary open angle glaucoma and underwent combined cataract surgery with Hydrus Microstent with a minimum of twelve months of follow-up data available. Outcome measures included mean number of ocular hypotensive medication prescribed, intraocular pressure, number of glaucoma secondary surgical interventions, corrected distance visual acuity, and visual field mean deviation. Results: A total of 280 eyes were identified that met the inclusion and exclusion criteria above. Mean medications improved from 2.3 ± 1.1 at baseline to 1.6 ± 1.3, 1.5 ± 1.3, 1.6 ± 1.3, 1.7 ± 1.4, and 2.5 ± 1.1 at 12, 24, 36, 48, and 60 months postoperatively, respectively. Intraocular pressure improved from 15.2 ± 4.1 mmHg at baseline to 12.8 ± 2.9 mmHg, 12.9 ± 2.8 mmHg, 13.0 ± 2.4 mmHg, 12.8 ± 3.1 mmHg, and 12.4 ± 2.5 mmHg at 12, 24, 36, 48, and 60 months postoperatively, respectively. Mean postoperative mean deviation was -3.8 ± 5.1, -3.9 ± 4.2, -2.9 ± 3.5, and -2.5 ± 3.6 dB at 12, 24, 36, and 48 months, respectively, compared to -5.4 ± 6.0 dB at baseline. Conclusion: The results of this study suggest that after combination cataract and Hydrus Microstent surgery, the number of glaucoma medications and intraocular pressure are reduced, and visual fields are stable through 4 years postoperatively. Additional data collected at 5 years postoperatively suggest persistent medication and intraocular pressure reduction, though cautious interpretation is warranted given substantial patient attrition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.